WO2010051056A3 - ANTI-FcεRI POLYPEPTIDES AND THEIR USES - Google Patents

ANTI-FcεRI POLYPEPTIDES AND THEIR USES Download PDF

Info

Publication number
WO2010051056A3
WO2010051056A3 PCT/US2009/036866 US2009036866W WO2010051056A3 WO 2010051056 A3 WO2010051056 A3 WO 2010051056A3 US 2009036866 W US2009036866 W US 2009036866W WO 2010051056 A3 WO2010051056 A3 WO 2010051056A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
polypeptides
uses
fcεri
anti
cra2
Prior art date
Application number
PCT/US2009/036866
Other languages
French (fr)
Other versions
WO2010051056A2 (en )
Inventor
Robert Mariani
Marc Siladi
Brad Hehli
Lillian Ho
Kassandra Macpherson
Aga Szydlik
Original Assignee
Ambrx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Novel antigen-binding polypeptides (FcERI-ABP) having one or more non-naturally occurring amino acids, and uses thereof are provided. The polypeptides are CRA2 polypeptides
PCT/US2009/036866 2008-03-11 2009-03-11 ANTI-FcεRI POLYPEPTIDES AND THEIR USES WO2010051056A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US3562608 true 2008-03-11 2008-03-11
US61/035,626 2008-03-11

Publications (2)

Publication Number Publication Date
WO2010051056A2 true WO2010051056A2 (en) 2010-05-06
WO2010051056A3 true true WO2010051056A3 (en) 2010-09-16

Family

ID=42129500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/036866 WO2010051056A3 (en) 2008-03-11 2009-03-11 ANTI-FcεRI POLYPEPTIDES AND THEIR USES

Country Status (1)

Country Link
WO (1) WO2010051056A3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875989A1 (en) * 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
KR20150048781A (en) 2012-08-31 2015-05-07 서트로 바이오파마, 인크. Modified amino acids comprising an azido group
EP3336103A1 (en) 2013-07-10 2018-06-20 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2018119413A1 (en) * 2016-12-22 2018-06-28 Lipidair, Llc Targeted delivery methods and compositions for antihistamines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050374A1 (en) * 2004-06-18 2008-02-28 Ambrx, Inc. Novel antigen-binding polypeptides and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050374A1 (en) * 2004-06-18 2008-02-28 Ambrx, Inc. Novel antigen-binding polypeptides and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKAHASHI ET AL.: "The High Affinity IgE Receptor (FceRl) as a Target for Anti-allergic Agents", ALLERGOLOGY INTERNATIONAL, vol. 54, 2005, pages 1 - 5 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides

Also Published As

Publication number Publication date Type
WO2010051056A2 (en) 2010-05-06 application

Similar Documents

Publication Publication Date Title
WO2008121767A3 (en) Stitched polypeptides
WO2011090760A4 (en) Heteroaryl compounds and uses thereof
WO2006091231A3 (en) Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006133089A3 (en) Improved human interferon molecules and their uses
WO2007073554A3 (en) Block copolymer particles
CA2681184A1 (en) Polythioether amine resins and compositions comprising same
WO2008070269A3 (en) Methods, software and systems for imaging
WO2010017387A3 (en) Lapatinib, salts thereof, processes and intermediates for their preparation
WO2006105362A3 (en) Biocompatible articles and related methods
WO2010006072A3 (en) Mtor modulators and uses thereof
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2012061290A3 (en) Pesticidal compositions and processes related thereto
WO2006104989A3 (en) Altered antibody fc regions and uses thereof
WO2008030558A3 (en) Modified human plasma polypeptide or fc scaffolds and their uses
WO2010106180A3 (en) Optimized fc variants
WO2008092117A3 (en) Immunoglobulins with modifications in the fcr binding region
GB0715896D0 (en) Microporous polymers, methods for the preparation thereof, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09823958

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09823958

Country of ref document: EP

Kind code of ref document: A2